Therapies for Long COVID in non-hospitalised individuals

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

The TLC Study or Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient-reported outcomes and immunology to targeted therapies.[1][2]

Funding[edit | edit source]

£2.2m over two years. Funded by the UK National Institute for Health Research (NIHR) and UK Research and Innovation.[3]

Results[edit | edit source]

None published yet.

Criticism[edit | edit source]

Investigators[edit | edit source]

  • Shamil Haroon, University of Birmingham - Principal Investigator
  • Melanie Calvert, University of Birmingham - Co-Principal Investigator[4]

Other researchers include Dr Krish Nirantharakumar, Dr Joht Singh Chandan, Dr Olalekan Lee Aiyegbusi, Professor Janet Lord, Professor David Wraith, Professor Alastair Denniston, Dr Sarah Hughes, Dr Louise Jackson, Dr Grace Turner, Dr Samantha Cruz Rivera, Dr Anuradhaa Subramanian, Professor Georgios Gkoutos, Professor Elizabeth Sapey, Professor Tom Marshall, Dr Christel McMullan, Professor Steven Marwaha, and COVID-19 survivor Gary Price who will also act as a co-investigator.

It also includes Dr Puja Myles and Dr Tim Williams, of the Medicines and Healthcare products Regulatory Agency (MRHA), and Dr Elin Haf Davies, of Aparito Limited.[3]

Project partners[edit | edit source]

News and articles[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]